WTFC has pulled back sharply after its Q2 print, but the analyst community and borrow market are both telling a calmer story than the price action suggests.
The stock closed Tuesday at $158.93, down 2.9% on the day and off 2.1% for the week. That follows the Q2 earnings release on July 21, which triggered a one-day move of roughly -3.3%. The decline is the dominant fact of the week — but it is worth framing: the stock is still up about 3% over the past month, meaning the post-earnings move has given back only part of a recent run. The retreat leaves WTFC sitting well below the average analyst price target of $180, implying roughly 13% upside from current levels.
The analyst response to the print has been measured rather than alarmed. Two actions landed this morning: TD Cowen trimmed its target by $1 to $183 while keeping a Buy rating, and DA Davidson moved in the opposite direction — raising its target from $185 to $190, also maintaining Buy. Both firms kept constructive ratings, framing the move as noise rather than a deterioration in the thesis. Truist and Barclays had both lifted targets earlier in the month, with Barclays sitting at $192 Overweight. The lone holdout is UBS, which reinstated coverage at Neutral with a $170 target on July 7 — a signal that at least one firm sees the valuation as fair at current levels. The Street's direction of travel remains positive: the overwhelmingly Buy-weighted consensus, ranked in the 100th percentile on analyst recommendation differential, has not broken. Bulls point to Wintrust's consistent loan and deposit growth, stable net interest margins, and solid expense management. Bears cite interest rate sensitivity, credit risk, and modest pressure on fee income as the key vulnerabilities.
The borrow and positioning data reinforce the picture of an uncrowded trade. Short interest edged up about 0.9% on the week to 3.7% of the free float — a modest pickup but still well within normal territory. The lending pool remains extraordinarily loose, with availability running at nearly 4,828% of outstanding short interest, meaning there are roughly 48 shares available to borrow for every one currently lent out. That reading is actually higher than the ~3,900% flagged in the pre-earnings note a day ago, as more shares have entered the pool. Cost to borrow eased to 0.46%, down from 0.59% before the print. Nothing in the lending market signals any short pressure building. The ORTEX short score has ticked down to 39.1, its lowest of the past two weeks, consistent with bears retreating rather than pressing. Options traders are similarly relaxed: the put/call ratio moved to 0.40, marginally above its 20-day average of 0.37 but nowhere near defensive territory. The PCR hit a 52-week high of 4.13 at some point in the past year — the current reading is a fraction of that extreme.
On valuation, the trailing P/E has drifted to around 11.8x and the price-to-book to 1.34x after the pullback — both modest multiples for a bank growing loans at this pace. The 90-day EPS momentum factor ranks in the 89th percentile, meaning forward estimate revisions have been running well ahead of the broader universe. The 30-day EPS momentum rank is softer at the 35th percentile, which may partly explain why a single cautious voice from UBS has found a foothold. Among close peers, the stock's week looks weak by comparison: UBSI gained 2.2% on the week and COLB added 1.9%, while ZION fell 1.9%, making WTFC's -2.1% more of a post-earnings idiosyncrasy than a sector-wide move.
The next test is whether the stock can stabilise around its current level and whether the gap to the analyst consensus — now spanning roughly $21 from price to mean target — begins to close. With no near-term earnings event on the calendar, the focus shifts to macro data on regional bank credit quality and any management commentary that emerges from investor meetings in the weeks ahead.
See the live data behind this article on ORTEX.
Open WTFC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
